Most Read Articles
Rachel Soon, 03 Mar 2020

Military pharmacist Captain Manvikram Singh Gill has become the first medical officer in the Malaysian Armed Forces (MAF) to be honoured with a Southeast Asian award for pharmacy professionals.

Jairia Dela Cruz, 15 Mar 2019
Denosumab appears to be a more attractive treatment option for glucocorticoid-induced osteoporosis compared with risedronate, with the former yielding superior improvements in spine and hip bone mineral density through 2 years and having a similar safety profile, according to a study.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

CLS-TA provides vision gains in patients with macular oedema

22 Feb 2020

A suprachoroidally injected CLS-TA, an investigational formulation of triamcinolone acetonide, yields significant improvements in vision of patients with macular oedema (ME), according to the results of the phase III PEACHTREE study.

PEACHTREE randomized 160 patients with ME secondary to noninfectious uveitis to receive suprachoroidally injected CLS-TA (n=96) or sham (n=64), administered at baseline and week 12. All patients had a pretreatment best corrected visual acuity (BCVA) score of ≥5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (20/800 Snellen equivalent) and ≤70 letters read (20/40) in the study eye.

The primary endpoint of an improvement of ≥15 ETDRS letters in BCVA at week 24 occurred with significantly greater frequency in the active treatment than in the control arm (47 percent vs 16 percent; p<0.001).

Results for the secondary endpoint of central subfield thickness were more favourable with CLS-TA, with a mean reduction of 153 μm as compared with 18 μm with sham treatment (p<0.001).

There were no reports of serious adverse events (AEs) related to treatment. Corticosteroid-associated AEs, specifically elevated intraocular pressure, occurred in 11.5 percent on CLS-TA and 15.6 percent on sham. Cataract AE rates were similar (7.3 percent and 6.3 percent, respectively).

According to researchers, the present data support the clinical use of suprachoroidally injected CLS-TA as a new treatment option for patients with ME related to noninfectious uveitis. Furthermore, PEACHTREE opens the way for investigations on suprachoroidal route to deliver therapeutics to choroidal and retinal tissues in a targeted approach.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 03 Mar 2020

Military pharmacist Captain Manvikram Singh Gill has become the first medical officer in the Malaysian Armed Forces (MAF) to be honoured with a Southeast Asian award for pharmacy professionals.

Jairia Dela Cruz, 15 Mar 2019
Denosumab appears to be a more attractive treatment option for glucocorticoid-induced osteoporosis compared with risedronate, with the former yielding superior improvements in spine and hip bone mineral density through 2 years and having a similar safety profile, according to a study.
03 Apr 2019
Long-term treatment with glucocorticoids (GC) is necessary in polymyalgia rheumatica (PMR), but preliminary data of a study suggests that use of amino bisphosphonates (N-BP) correlates with GC discontinuation in the management of PMR.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders.